Company intelligence / Profile preview

Nanjing Anji Biotechnology

Nanjing, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Nanjing Anji Biotechnology possesses key technological capabilities in endogenous peptide discovery and peptide drug design. The company has demonstrated in vitro and in vivo efficacy of antibody fusion proteins targeting multiple cancer-related pathways. Research includes development of PD-1 binding peptides for cancer immunotherapy and multifunctional fusion proteins showing significant antitumor effects in xenograft models[8].

Therapeutic areas: ImmunologyNeurologyPulmonologyOncologyOphthalmology
Modalities: PeptidePeptide-drug conjugateRecombinant polypeptideSmall molecule
Industry: Biotech

Partnerships

Amphastar Pharmaceuticals (exclusive licensing agreement for three peptides in US and Canada, announced August 12, 2025)China Pharmaceutical University (collaboration on drug development)

Beyond the preview

Go deeper on Nanjing Anji Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanjing Anji Biotechnology.

Explore the full profile